Isracann Biosciences Inc. (CSE:IPOT, XFRA:A2PT0E, OTC:ISCNF) (the “Company”) an Israel-based company focused on becoming a premier low cost, high quality cannabis producer for both domestic and European export sales, is pleased to announce it has entered into an MOU for a joint venture with an additional farm property consisting of a late stage buildout of a cannabis cultivation facility in an agricultural centre proximal to several licensed producers (LP’s) west of Be’er Sheva, Israel (the “Be’er Sheva Farm”). Under the joint venture, the Company will capitalize the buildout of the remaining construction in return for an economic interest in the project in compliance with Israeli laws. Terms of the joint venture will be released upon signing of a definitive agreement, which is subject to continued due diligence of the Be’er Sheva Farm by the Company.

The Be’er Sheva Farm consists of over 880,000 sq. ft. of agricultural land with two recently assembled steel greenhouse structures having a footprint of nearly 200,000 sq. ft. Upon full build-out the facility will represent an approximate 100% increase in the Company’s current potential production capacity from its existing Nir Israel farm. The Be’er Sheva Farm also provides unused land with the potential for four times cultivation expansion capability. The new facility is designed to cannabis production standards and is ready to be enclosed with high quality application-specific polycarbonate cladding. The facility has all construction and land use permits in-place and an experienced and knowledgeable cultivation team which has local agronomic expertise with regional cannabis operations.


Isracann CEO Darryl Jones advises, “Our agronomic consultants brought this enterprise to our attention recently and the economics of the opportunity impressed us enough to move quickly to lock in a partnership. The facility is poised to greatly expand our existing footprint and advances our timeline to production by several months.”

Isracann has moved quickly to develop a definitive agreement subject to completion of commercial due diligence. A preliminary assessment by Isracann’s agronomic team projects full scale planting during the upcoming 2020 spring season. Initial production projections indicate a first-year yield consistent with the Company’s Nir Israel farm projected output.

Matt Chatterton, VP Operations for Isracann recently visited the Be’er Sheva Farm and comments, “We’ve been evaluating several opportunities to expedite our commercialization plans and based on my inspection of the property this farm offers the ability to shorten our time-to-market. The fundamentals are already in place, including building permits, and the basic infrastructure is already constructed which accelerates timing. Once we conclude our due diligence efforts, the proposed plan will be to advance the technical efforts including completion of the greenhouse and concurrently implementing a project characterization strategy in preparation to planting. There is still a lot of work to complete, but our efforts at our Nir Israel farm have already provided us with regional business relationships, experienced advisors, and extensive preparations that we can readily extend and implement across both locations.”

“The region has already proven suitable for high quality cannabis production,” continues Company CEO Jones. “Of significant interest is that the farm operator will participate in the arrangement and is a highly experienced manager of cost effective large-scale agricultural operations within the region. There are also several corporate and economic advantages open to us as we move ahead to finalize our definitive agreement. The opportunity to achieve production sooner than anticipated is a very attractive part of this strategic acquisition and directly reflects our commitment to our partners, stakeholders and shareholders alike as we grow our presence as cannabis industry leaders in Israel.”

ON BEHALF OF THE BOARD OF DIRECTORS

“Darryl Jones”

Darryl Jones
Chief Executive Officer and President

About Isracann Biosciences Inc. (CSE:IPOT, XFRA:A2PT0E, OTC:ISCNF)
Isracann is an Israeli-based cannabis company focused on becoming a premier cannabis producer offering low-cost production targeting undersupplied, major European marketplaces. Based in Israel’s agricultural sector, Isracann will leverage its development within the most experienced country in the world with respect to cannabis research. The Company has secured agreements within Israel for medicinal marijuana cultivation. For more information visit: www.isracann.com.

The CSE does not accept responsibility for the adequacy or accuracy of this release.

All statements, other than statements of historical fact, included herein are forward-looking statements that involve various risks and uncertainties. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. Important factors that could cause actual results to differ, materially from the Company’s expectations are disclosed in the Company’s documents filed from time to time with the Canadian Securities Exchange, the British Columbia Securities Commission, the Ontario Securities Commission, and the Alberta Securities Commission.

Click here to connect with Isracann Biosciences Inc. (CSE:IPOT) for an Investor Presentation.

Source

Agreement propels development of safe and effective proprietary products and formulations for the emerging psychedelic industry

Optimi Health Corp. (CSE: OPTI) (“Optimi” or the “Company”), developers of a vertically integrated functional mushroom brand focused on the health and wellness sector, is pleased to announce that effective January 4, 2021, it entered into a lab services agreement with Numinus Wellness Inc. (“Numinus“). Recognized as an early leader in developing and supporting the safe, evidence-based, accessible use of psychedelic-assisted psychotherapies (PAP), Numinus is aiding Optimi’s mission to further the research and development of Canadian-grown psilocybin-producing mushrooms and related product formulations.

Keep reading... Show less

Nextleaf Solutions Ltd. (CSE: OILS) (OTCQB: OILFF) (“Nextleaf”, “OILS”, or the “Company”), the world’s most innovative cannabis processor, is pleased to provide shareholders with the following corporate update:

Nextleaf Comments on Financial Results from Q1 Financials

Keep reading... Show less

Hill Street Beverage Company Inc. (TSXV: BEER) (“Hill Street” or the “Company”) reported its second quarter results for the period ended December 31, 2020. A complete set of financial statements and Management’s Discussion & Analysis has been filed at www.sedar.com. All dollar figures are quoted in Canadian dollars.

The second quarter of FY21, saw continued momentum for the Company despite ongoing pandemic related challenges. Net revenue grew 8% to $745,748 from $689,276 versus the same quarter year ago. The Company also saw significant improvement on its bottom line, reducing its net loss by 50% from ($.956) million to ($.481) million, year over year for the quarter, as a result of improved gross margin and cost management efforts. On December 9, 2020, the company announced the closing of the acquisition of substantially all of the assets of Lexaria Canpharm (“Canpharm“), the cannabis products division of Lexaria Biosciences, resulting in the addition of a new B2B Line of Business.

Keep reading... Show less

Royalty Model Provides Access to Early Stage Licenced U.S. Cannabis Companies and Leverage to High-Margin Revenues

FinCanna Capital Corp. (“FinCanna” or the “Company”) (CSE:CALI), a royalty company for the licensed U.S. cannabis industry, is pleased to provide a corporate update further to its recently announced upsized financing of $2 million

Keep reading... Show less

Significant progress made as Numinus-sponsored PRIME study on psilocybin-assisted psychotherapy for opioid, stimulant and/or alcohol use disorders enters pre-implementation stage

Numinus Wellness Inc. (“Numinus” or the “Company”) (TSXV: NUMI), a company creating an ecosystem of health solutions centered around developing and supporting the safe, evidence-based, accessible use of psychedelic-assisted psychotherapies (PAP), and Syreon Corporation (Syreon), a global contract research organization with expertise in conducting clinical trials across a broad range of diseases, are pleased to share that significant progress has been made in the single-arm, open-label compassionate access 1 trial of Psilocybin-Research Intervention with Motivational Enhancement (PRIME) for substance use disorders. Currently in the development stage, the PRIME study will assess the efficacy and safety of psilocybin-assisted motivational enhancement therapy.

Keep reading... Show less